The ultrasonic electrosurgery devices market size is expected to increase from USD 3.95 billion in 2025 to USD 4.15 billion in 2026 and reach USD 5.33 billion by 2031, growing at a CAGR of 5.12% over 2026-2031. This report Segments the Industry Into by Product (Generators and Consumables), by Type (High-Intensity Focused Ultrasonic (HIFU) Ablators, and More.), by Applications, by End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).
Active blades remain the largest consumable sub-segment because they are mandatory in laparoscopy, gynecology, and oncology. Reprocessed options threaten new-unit sales, evidenced by Stryker’s July 2024 FDA clearance that lets ASCs cut costs by half. Vendors respond with durability claims such as the Harmonic 700’s 24-fold longer pad life. Accessory bundles, including footswitches and cables, secure the ultrasonic electrosurgery devices market share of incumbents by locking buyers into proprietary connectors.
HIFU ablators captured 42.2% share in 2025 on the back of InSightec Exablate approvals for essential tremor, uterine fibroids, and bone metastases. These systems integrate MR imaging that guides real-time energy deposition which helps avoid collateral damage. Ultrasonic surgical ablation platforms will accelerate at 7.45% CAGR as oncology and orthopedic surgeons adopt probes that blend cutting, coagulation, and cavitation. The ultrasonic electrosurgery devices market size for these applications gains from AI-driven planning that tailors pulse sequences to tissue impedance.
Shock wave therapy stays niche because reimbursement often runs flat, but orthopedic debridement devices from Bioventus and BOWA cut an opening in ENT micro-surgery niches. Chinese regulators now classify surgical ultrasound as Class III, delaying entry yet affirming state confidence in high-risk use. Vendors that clear that barrier stand to tap vast procedure volumes in China’s tertiary hospitals.
Asia-Pacific is on track for a 6.54% CAGR through 2031. Japan anchors regional revenue with Olympus Therapeutic Solutions sales above JPY 360 billion in FY2025 and local launches of THUNDERBEAT II. China’s Class III designation in August 2023 raises barriers but also signals official endorsement, prompting provincial hospitals to budget for high-risk soft-tissue systems. India, Australia, and South Korea follow with procedure growth tied to aging populations and expanding private insurance.
Europe holds about 28% of global takings. Germany, the United Kingdom, and France make up 60% of regional demand, yet MDR bottlenecks slow new platform rollouts. Olympus introduced THUNDERBEAT II across EU markets in October 2025, emphasizing lower probe temperature to satisfy surgeon safety concerns. Italy and Spain emphasize consumable-first procurement under austerity rules. South America and Middle East & Africa contribute the remainder, with Gulf Cooperation Council hospitals spending on energy upgrades and Brazilian importers offsetting tariffs through local assembly deals.
Global Ultrasonic Electrosurgery Devices Market Trends and Insights
Rising Global Surgical Procedure Volume
Hospitals performed almost 599 000 bariatric operations in 2021, up from 508 000 in 2020, while sleeve gastrectomy accounted for about 70% of cases and robot assistance reached 30% of United States procedures by 2022. Swedish registries also logged steady growth in atrial fibrillation ablations, confirming broader procedural expansion that directly lifts ultrasonic dissection demand. Meta-analysis shows these systems save an average 19.78 minutes of operative time and 45.25 mL of blood loss compared with conventional electrosurgery. The sharpest rise appears in Asia-Pacific where aging populations and chronic diseases fuel operating room volumes, prompting hospitals to invest in platforms that process more cases per theater.Growing Preference for Minimally Invasive Surgery
Minimally invasive techniques captured 63.21% of 2025 revenue, supported by persistent shifts from inpatient to outpatient settings documented in United States Healthcare Cost and Utilization Project data. In a 265-patient trial completed December 2024, Ethicon Harmonic 1100 achieved 99% hemostasis, reinforcing its alignment with laparoscopic workflows. A 2024 study from Iran found higher postoperative hemoglobin and fewer complications when harmonic instruments replaced monopolar tools during hysterectomy. CMS separate payments for non-opioid devices effective January 2025 create a direct reimbursement tailwind for ultrasonic solutions that curb opioid use.High Capital and Consumable Costs of Ultrasonic Systems
Generator platforms cost USD 15 000 to USD 40 000 and single-use handpieces run USD 200 to USD 600, straining ASC budgets even after the CMS 2.9% payment bump. January 2024 device offset rules further deduct consumable expenses from payments, tightening margins unless centers negotiate bundle discounts. Stryker won July 2024 clearance to sell reprocessed Harmonic shears at 30% to 50% discounts, offering an immediate workaround for budget-pressed providers. Tiered product portfolios that keep entry pricing low without cannibalizing premium hospital lines have become a must-have for vendors.Other drivers and restraints analyzed in the detailed report include:
- Technological Advancements in Ultrasonic Energy Platforms
- Expanding Ambulatory Surgical Center Footprint Worldwide
- Stringent Multiregional Regulatory Approval Processes
Segment Analysis
Consumables controlled 56.65% revenue in 2025, powered by per-procedure demand for active blades, shears, and handpieces, yet generators deliver higher gross margin and will grow at 7.54% CAGR through 2031. Hospitals invest because multi-energy consoles eliminate the need to dock separate ultrasonic and bipolar units. Olympus THUNDERBEAT II adds a standalone ultrasonic mode that surgeons toggle without exchanging tools, proving the premium generator case. The ultrasonic electrosurgery devices market size for generators is set to climb steadily as facilities retire single-energy consoles.Active blades remain the largest consumable sub-segment because they are mandatory in laparoscopy, gynecology, and oncology. Reprocessed options threaten new-unit sales, evidenced by Stryker’s July 2024 FDA clearance that lets ASCs cut costs by half. Vendors respond with durability claims such as the Harmonic 700’s 24-fold longer pad life. Accessory bundles, including footswitches and cables, secure the ultrasonic electrosurgery devices market share of incumbents by locking buyers into proprietary connectors.
HIFU ablators captured 42.2% share in 2025 on the back of InSightec Exablate approvals for essential tremor, uterine fibroids, and bone metastases. These systems integrate MR imaging that guides real-time energy deposition which helps avoid collateral damage. Ultrasonic surgical ablation platforms will accelerate at 7.45% CAGR as oncology and orthopedic surgeons adopt probes that blend cutting, coagulation, and cavitation. The ultrasonic electrosurgery devices market size for these applications gains from AI-driven planning that tailors pulse sequences to tissue impedance.
Shock wave therapy stays niche because reimbursement often runs flat, but orthopedic debridement devices from Bioventus and BOWA cut an opening in ENT micro-surgery niches. Chinese regulators now classify surgical ultrasound as Class III, delaying entry yet affirming state confidence in high-risk use. Vendors that clear that barrier stand to tap vast procedure volumes in China’s tertiary hospitals.
Complete Report Scope:
- By Product
- Generators
- Consumables
- Active Blades & Shears
- Handpieces & Tips
- Accessories & Cables
- By Type
- HIFU Ablators
- MR-Guided FUS Ablators
- Ultrasonic Surgical Ablation Systems
- Shock Wave Therapy Systems
- Ultrasonic Dissection & Coagulation Systems
- By Procedure
- Minimally-Invasive / Laparoscopic Surgery
- Robot-Assisted Surgery
- Open Surgery
- By Application
- Cardiology (Electrophysiology & Cardiothoracic)
- Gynecology
- General Surgery
- Urology
- Bariatric Surgery
- Orthopedic Surgery
- Oncology (Tumor Ablation)
- Others (Neurosurgery, ENT)
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Academic & Research Institutes
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America accounted for 40.43% of 2025 global revenue because Medicare’s 2.9% payment lift and the separate non-opioid device pathway directly reward ultrasonic adoption. Canada and Mexico add smaller totals, with Mexican private hospitals marketing bariatric and cosmetic bundles to inbound medical tourists. FDA de novo clearances for Exablate show regulator openness to non-invasive ablation, a factor that keeps capital pipelines healthy.Asia-Pacific is on track for a 6.54% CAGR through 2031. Japan anchors regional revenue with Olympus Therapeutic Solutions sales above JPY 360 billion in FY2025 and local launches of THUNDERBEAT II. China’s Class III designation in August 2023 raises barriers but also signals official endorsement, prompting provincial hospitals to budget for high-risk soft-tissue systems. India, Australia, and South Korea follow with procedure growth tied to aging populations and expanding private insurance.
Europe holds about 28% of global takings. Germany, the United Kingdom, and France make up 60% of regional demand, yet MDR bottlenecks slow new platform rollouts. Olympus introduced THUNDERBEAT II across EU markets in October 2025, emphasizing lower probe temperature to satisfy surgeon safety concerns. Italy and Spain emphasize consumable-first procurement under austerity rules. South America and Middle East & Africa contribute the remainder, with Gulf Cooperation Council hospitals spending on energy upgrades and Brazilian importers offsetting tariffs through local assembly deals.
List of Companies Covered in this Report:
- Advanced Instrumentations
- Alfa Medtech
- B. Braun
- Bioventus LLC (Misonix, Inc.)
- BOWA Medical
- Chongqing Haifu Medical
- Conmed
- Insightec Ltd.
- Italia Medica
- Johnson & Johnson
- KLS Martin Group
- Medtronic
- Miconvey Technologies
- Olympus
- Reach Surgical
- Silfradent Srl
- Sonablate Corp.
- SonaCare Medical
- Söring GmbH
- Stryker
- Theraclion SA
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advanced Instrumentations
- Alfa Medtech
- B. Braun Melsungen AG
- Bioventus LLC (Misonix, Inc.)
- BOWA-electronic GmbH & Co. KG
- Chongqing Haifu Medical
- ConMed Corporation
- Insightec Ltd.
- Italia Medica
- Johnson & Johnson (Ethicon)
- KLS Martin Group
- Medtronic PLC
- Miconvey Technologies
- Olympus Corporation
- Reach Surgical
- Silfradent Srl
- Sonablate Corp.
- SonaCare Medical
- Söring GmbH
- Stryker Corporation
- Theraclion SA
